Davide Capodanno: Independent Investigators Lead the First Head to Head DOAC Comparison
Davide Capodanno, Full Professor of Cardiology at the University of Catania, shared a post on LinkedIn about a recent article by Lana A. Castellucci et al, published in NEJM:
“Finally published: the COBRRA trial, the first randomized head-to-head comparison of major DOACs – something the companies would never have done themselves, as a direct confrontation goes beyond their commercial interests.
This was driven by independent investigators.
The results somewhat support the idea of apixaban being the ‘safer’ DOAC.
That said, the list of study limitations is long, and for me, labeling something as ‘safe’ is not enough — after all, even placebo is ‘safe’ when it comes to bleeding.”
Ali Kamiar, Graduate Student Research Assistant Graduate Student, Research Assistant at University of Miami, Miller School of Medicine, reposted Davide Capodanno’s post on LinkedIn.
“Valuable independent evidence comparing major DOACs. Highlights the importance of critically evaluating both safety endpoints and study limitations when translating data into clinical practice.”
Title: Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism
Authors: Lana A. Castellucci, Vivien M. Chen, Michael J. Kovacs, Alejandro Lazo-Langner, Peter Greenstreet, Susan Kahn, Benoit Côté, Sam Schulman, Kerstin de Wit, James Douketis, Deepa Suryanarayan, Tony Wan, Erik Yeo, Genevieve Le Templier, Huyen A. Tran, Abbey Willcox, Helen J. Crowther, Ritam Prasad, Sudeep Shivakumar, Etimbuk Umana, Fionnuala Ni Ainle, Tobias Tritschler, Stefano Barco, Jean-Philippe Galanaud, Marc Blondon, Lisa Baumann Kreuziger, Susan Solymoss, Clive Kearon, Erin Thomas, Tim Ramsay, Gregoire Le Gal, Marc Rodger
Read the Full Article on NEJM
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 30, 2026, 01:52Javed Anees: DADA2 – When a Young Stroke Is More Than a Stroke
-
Sep 30, 2026, 01:51How a Venous Thrombus Becomes Revascularized – ISTH
-
Sep 29, 2026, 22:45Victor Agunyego: Paracetamol – The Most Common Drug We Underestimate
-
Sep 29, 2026, 22:42Nova Sinclair: Advancing the Future of Hematology – Meet Our 2027 Organizing Committee
-
Sep 29, 2026, 22:41Lorenz Räber: Intracoronary Imaging in PCI – Why, When, How, and Which Modality?
-
Sep 29, 2026, 22:31Selma Turkovic: Pleased to Deliver the Opening Presentation at Kingston Hospital
-
Sep 29, 2026, 22:31Miguel Teran: Ultrasound and Simulation in Arterial Blood Sampling
-
Sep 29, 2026, 22:28Mohammad Refaei: Navigating Your Career in Hematology From Training to Practice
-
Sep 29, 2026, 22:27Matteo Foschi: 10 Clinical Pearls for Antithrombotic Therapy in Secondary Stroke Prevention